Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum ABFRA:6Y1 -5.46%53 Days Payable is 0.00 as of Jul. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 53/100 and a GF Value™ of €1.41 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Integrum AB ranks better than 61.81% on this metric.
The historical rank and industry rank for Integrum AB's Days Payable or its related term are showing as below:
FRA:6Y1'
s Days Payable Range Over the Past 10 Years
Min: 102.57 Med: 227.11 Max: 303.1
Current: 116.22
During the past 12 years, Integrum AB's highest Days Payable was 303.10. The lowest was 102.57. And the median was 227.11.
FRA:6Y1's Days Payable is ranked better than 61.81% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.68
vs FRA:6Y1: 116.22
Integrum AB's Days Payable
declined
from Jul. 2025 (178.08) to Jul. 2026 (0.00).
It may suggest that Integrum ABaccelerated paying its suppliers.
The historical data trend for Integrum AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Integrum AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Integrum AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Integrum AB's Days Payable for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrum AB (FRA:6Y1) has a Days Payable of 0.00 as of Jul. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrum AB and its competitors. Over the past decade, Integrum AB's Days Payable has ranged from 102.57 to 303.10. According to the industry distribution chart, Integrum AB ranks #304 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Integrum AB's Days Payable too high?
Integrum AB's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 102.57 to a high of 303.10. Based on the distribution chart, Integrum AB ranks #304 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Integrum AB has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #304 out of 796 companies for Days Payable. This puts Integrum AB in the upper half of its industry. The industry median Days Payable is 68.68. Historically, Integrum AB's own Days Payable has ranged from 102.57 to 303.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.68, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.41, compared to a current price of €0.78 — trading 44.8% below its estimated fair value. The current Days Payable is 0.00. Integrum AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current Days Payable is 0.00 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (FRA:6Y1) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of €0.78 is trading 44.8% below its estimated GF Value™ of €1.41.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for FRA:6Y1:
Days Payable: 0.00
GF Value™: €1.41 vs. price of €0.78 (44.8% below fair value)
No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
53GF Score
Get the complete analysis for FRA:6Y1
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Y1 has been successfully added to your 
